BEIJING, March 01, 2026 (GLOBE NEWSWIRE) — InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that its next generation TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), for the treatment of pediatric patients (aged 2 to 12) with solid tumors harboring NTRK gene fusions. Priority review is one of the key policies introduced by the CDE to accelerate drug approval. Read More
Source link
¡Argentina está de regreso! La albiceleste remonta en un duelo cardíaco ante Egipto
IE 11 no es compatible. Para una experiencia óptima, visite nuestro sitio en otro navegador. SIGUIENTE Enzo Fernández anota el 3-2 para dar la vuelta a Egipto 02:48 Messi se…





